Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Mesoblast (MSB) shares

Learn how to easily invest in Mesoblast shares.

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

A$1.27
current price
A$-0.03
change
-2.3077%
change %

How to buy shares in Mesoblast

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Mesoblast. Find the share by name or ticker symbol: MSB. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Mesoblast reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price of A$1.27, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Mesoblast, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Mesoblast. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Price details for Mesoblast (MSB)

Open A$1.3 Previous close A$1.3
High A$1.3 Change A$-0.03
Low A$1.27 Change % -2.3077%
Close A$1.27 Timestamp 1642546800
Volume N/A GMT offset 0

Mesoblast stock price

Use our graph to track the performance of MSB stocks over time.

Mesoblast company summary

Information last updated 2022-01-15.

Mesoblast (MSB) is a leading Biotechnology business based in Australia. Mesoblast (MSB) is listed on the ASX and employs 83 staff.

Profile

Industry Biotechnology Currency symbol A$
Code MSB Country name Australia
Type Common Stock Country ISO AU
Name Mesoblast Limited ISIN AU000000MSB8
Exchange AU CUSIP N/A
Currency code AUD Sector Healthcare
Currency name Australian Dollar Full-time employees 83

Detailed company information

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Go to site